Danaher Corporation (DHR) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This summary covers Danaher Corporation's Form 10-Q for the quarterly period ended March 28, 2025. Danaher is a diversified science and technology company operating through three segments: Biotechnology, Life Sciences, and Diagnostics. The company reported a large accelerated filer status with 715.7 million shares of common stock outstanding as of April 16, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Sales (Revenue) | $5,741 million | $5,796 million |
| Net Earnings | $954 million | $1,088 million |
| Diluted EPS | $1.32 | $1.45 |
| Operating Profit | $1,274 million | $1,312 million |
| Operating Margin | 22.2% | 22.6% |
| Gross Margin | 61.2% | 60.2% |
| Operating Cash Flow | $1,299 million | $1,739 million |
| Cash and Equivalents (Ending) | $1,993 million | $7,031 million |
| Total Debt | $16,477 million | $16,005 million |
Material Changes vs. Prior Period
- Revenue Decline: Total sales decreased 1.0% year-over-year. Core sales were flat, with growth in Biotechnology offset by declines in Life Sciences and Diagnostics. Foreign currency negatively impacted sales by 1.5%.
- Profitability Pressure: Net earnings declined 12.3% due to increased operating expenses, investment losses, and higher net interest expense. Operating margins compressed 40 basis points.
- Segment Performance:
- Biotechnology: Sales grew 6.0% (Core sales +7.0%); Operating profit rose to $441 million (margin 27.4%).
- Life Sciences: Sales declined 3.5% (Core sales -4.0%); Operating profit fell to $201 million (margin 12.0%).
- Diagnostics: Sales declined 3.0% (Core sales -1.5%); Operating profit dropped to $718 million (margin 29.3%).
- Unusual Items: The company recorded a $15 million impairment charge for a Biotechnology facility and recognized a $9 million gain on the sale of a product line. Investment losses totaled $90 million, compared to $37 million in the prior year.
- Cash Flow: Operating cash flow decreased 25% to $1.3 billion, driven by lower net earnings and working capital changes. Financing activities used $1.3 billion, primarily due to $1.1 billion in share repurchases.
Guidance, Outlook, and Risks
- Tariff Impact: New U.S. tariffs implemented in Q2 2025 are expected to incur incremental costs of "several hundred million dollars" in 2025. Management anticipates offsetting these via supply chain adjustments and cost savings, though demand impacts remain a risk.
- Outlook: Management expects end-market demand for the remainder of 2025 to be relatively consistent with Q1 2025.
- Tax Rate: The effective tax rate for the remainder of 2025 is projected to be approximately 17.0%.
- Capital Allocation: The company repurchased 4.5 million shares for $1.1 billion in Q1. Approximately 12 million shares remain available under the current repurchase program. A quarterly dividend of $0.32 per share was declared.
- Risks: Key risks include geopolitical tensions, trade policy changes (tariffs), foreign currency fluctuations, and the ability to offset cost increases through pricing or productivity.
Investor Verification Checklist
- Verify the magnitude of incremental tariff costs and the specific supply chain adjustments planned to mitigate them.
- Monitor the trajectory of core sales in the Life Sciences and Diagnostics segments, particularly in China and North America.
- Assess the sustainability of the Biotechnology segment's margin expansion given the $15 million impairment charge.
- Review the company's ability to maintain operating cash flow levels given the significant reduction in Q1 2025.
- Track the effective tax rate against the 17.0% guidance, considering discrete tax benefits and global earnings mix.